A share price of Boston Scientific Corp [BSX] is currently trading at $104.65, up 1.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BSX shares have gain 0.76% over the last week, with a monthly amount glided 3.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Boston Scientific Corp [NYSE: BSX] stock has seen the most recent analyst activity on June 16, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $118. Previously, Needham upgraded its rating to Buy on April 16, 2025, and kept the price target unchanged to $113. On January 10, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $108 on the stock. Needham downgraded its rating to a Hold. Goldman initiated its recommendation with a Buy and recommended $90 as its price target on May 30, 2024. Mizuho upgraded its rating to Buy for this stock on February 01, 2024, and upped its price target to $80. In a note dated July 19, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $59 on this stock.
Boston Scientific Corp experienced fluctuations in its stock price throughout the past year between $71.88 and $107.53. Currently, Wall Street analysts expect the stock to reach $120.8 within the next 12 months. Boston Scientific Corp [NYSE: BSX] shares were valued at $104.65 at the most recent close of the market. An investor can expect a potential return of 15.43% based on the average BSX price forecast.
Analyzing the BSX fundamentals
Trailing Twelve Months sales for Boston Scientific Corp [NYSE:BSX] were 17.55B which represents 20.93% growth. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.1 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Boston Scientific Corp [NYSE:BSX] is 1.45. Also, the Quick Ratio is 0.88, while the Cash Ratio stands at 0.14. Considering the valuation of this stock, the price to sales ratio is 8.82, the price to book ratio is 6.97 and price to earnings (TTM) ratio is 76.68.
Transactions by insiders
Recent insider trading involved Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology, that happened on Jul 01 ’25 when 50000.0 shares were sold. Officer, JOSEPH M FITZGERALD completed a deal on Jul 01 ’25 to buy 50000.0 shares. Meanwhile, EVP & Group Pres, Cardiology Fitzgerald Joseph Michael sold 56372.0 shares on Jun 04 ’25.
